Star Combo Pharma Limited
Star Combo Pharma Limited (S66.AX) Stock Overview
Explore Star Combo Pharma Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
20.3M
P/E Ratio
17.15
EPS (TTM)
$0.01
ROE
0.04%
S66.AX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Star Combo Pharma Limited (S66.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 48.68, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.12.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.15 and a market capitalization of 20.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. The company operates in two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products. The company provides its products through e-commerce platform to Chinese health product consumers; and two retail stores in Sydney. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Su Zhang
171-177 Woodpark Road, Smithfield, NSW
2018